Venus Remedies [VENUSREM] vs Wanbury [WANBURY] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Venus Remedies Ltd. wins in 11 metrics, Wanbury Ltd. wins in 7 metrics, with 0 ties. Venus Remedies Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Venus Remedies Ltd. | Wanbury Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 16.64 | 13.50 | Wanbury Ltd. |
| Price-to-Book Ratio | 2.14 | 14.28 | Venus Remedies Ltd. |
| Debt-to-Equity Ratio | 2.42 | 1.83 | Wanbury Ltd. |
| PEG Ratio | 0.54 | 0.01 | Wanbury Ltd. |
| EV/EBITDA | 9.49 | 12.27 | Venus Remedies Ltd. |
| Profit Margin (TTM) | 10.85% | -25.90% | Venus Remedies Ltd. |
| Operating Margin (TTM) | 17.18% | 5.49% | Venus Remedies Ltd. |
| EBITDA Margin (TTM) | 17.18% | 5.49% | Venus Remedies Ltd. |
| Return on Equity | 8.08% | 51.51% | Wanbury Ltd. |
| Return on Assets (TTM) | 6.33% | 7.38% | Wanbury Ltd. |
| Free Cash Flow (TTM) | $683.65M | $-229.26M | Venus Remedies Ltd. |
| 1-Year Return | 293.07% | -12.06% | Venus Remedies Ltd. |
| Price-to-Sales Ratio (TTM) | 1.81 | 2.43 | Venus Remedies Ltd. |
| Enterprise Value | $10.48B | $10.75B | Wanbury Ltd. |
| EV/Revenue Ratio | 1.49 | 1.81 | Venus Remedies Ltd. |
| Gross Profit Margin (TTM) | 52.15% | 57.65% | Wanbury Ltd. |
| Revenue per Share (TTM) | $526 | $162 | Venus Remedies Ltd. |
| Earnings per Share (Diluted) | $57.07 | $19.13 | Venus Remedies Ltd. |
| Beta (Stock Volatility) | 0.04 | N/A | N/A |
Venus Remedies Ltd. vs Wanbury Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Venus Remedies Ltd. | 4.76% | 11.07% | 106.51% | 106.53% | 140.13% | 147.60% |
| Wanbury Ltd. | -2.62% | 5.92% | 4.39% | 8.20% | 11.44% | 16.28% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Venus Remedies Ltd. | 293.07% | 631.88% | 1,305.94% | 1,305.94% | 354.83% | 354.89% |
| Wanbury Ltd. | -12.06% | 387.22% | 180.87% | 561.57% | 788.51% | 103.07% |
Performance & Financial Health Analysis: Venus Remedies Ltd. vs Wanbury Ltd.
| Metric | VENUSREM | WANBURY |
|---|---|---|
| Market Information | ||
| Market Cap | ₹12.71B | ₹9.02B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 65,711 | 62,333 |
| 90 Day Avg. Volume | 64,772 | 49,348 |
| Last Close | ₹1,883.00 | ₹267.35 |
| 52 Week Range | ₹416.00 - ₹1,887.30 | ₹161.50 - ₹320.95 |
| % from 52W High | -0.23% | -16.70% |
| All-Time High | ₹1,887.30 (Jun 15, 2026) | ₹329.70 (May 12, 2025) |
| % from All-Time High | -0.23% | -18.91% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.02% | -0.19% |
| Quarterly Earnings Growth | 0.31% | 0.22% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | -0.26% |
| Operating Margin (TTM) | 0.17% | 0.05% |
| Return on Equity (TTM) | 0.08% | 0.52% |
| Debt to Equity (MRQ) | 2.42 | 1.83 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹444.63 | ₹18.09 |
| Cash per Share (MRQ) | ₹176.40 | N/A |
| Operating Cash Flow (TTM) | ₹883.16M | ₹341.38M |
| Levered Free Cash Flow (TTM) | ₹453.15M | ₹305.30M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Venus Remedies Ltd. vs Wanbury Ltd.
| Metric | VENUSREM (Apr 26, 2026) | WANBURY (Apr 26, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 16.64 | 13.50 |
| Forward P/E | N/A | N/A |
| PEG Ratio | 0.54 | 0.01 |
| Price to Sales (TTM) | 1.81 | 2.43 |
| Price to Book (MRQ) | 2.14 | 14.28 |
| Market Capitalization | ||
| Market Capitalization | ₹12.71B | ₹9.02B |
| Enterprise Value | ₹10.48B | ₹10.75B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.49 | 1.81 |
| Enterprise to EBITDA | 9.49 | 12.27 |
| Risk & Other Metrics | ||
| Beta | 0.04 | N/A |
| Book Value per Share (MRQ) | ₹444.63 | ₹18.09 |
Financial Statements Comparison: Venus Remedies Ltd. vs Wanbury Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | VENUSREM (2025) | WANBURY (2025) |
|---|---|---|
| Revenue/Sales | 6.47B | 5.94B |
| Cost of Goods Sold | 4.02B | 3.01B |
| COGS % of Revenue | 62.1% | 50.8% |
| Gross Profit | 2.45B | 2.92B |
| Gross Margin | 37.9% | 49.2% |
| Research & Development | 180.85M | N/A |
| Operating Income (EBIT) | 410.23M | 702.53M |
| Operating Margin | 6.3% | 11.8% |
| EBITDA | 828.57M | 876.35M |
| EBITDA Margin | 12.8% | 14.8% |
| Pre-Tax Income | 718.26M | 295.51M |
| Pre-Tax Income % of Revenue | 11.1% | 5.0% |
| Income Tax | 265.12M | -9.79M |
| Income Tax % of Revenue | 4.1% | -0.2% |
| Net Income (Profit) | 453.15M | 305.30M |
| Profit Margin | 7.0% | 5.1% |
Balance Sheet & Liquidity Metrics
| Metric | VENUSREM (2025) | WANBURY (2025) |
|---|---|---|
| Cash & Equivalents | 575.23M | 40.61M |
| Total Current Assets | 4.52B | 1.93B |
| Total Current Assets % of Revenue | 69.8% | 32.6% |
| Total Current Liabilities | 1.36B | 1.75B |
| Total Current Liabilities % of Revenue | 21.1% | 29.4% |
| Long-Term Debt | 0 | 1.61B |
| Long-Term Debt % of Revenue | 0.0% | 27.1% |
| Total Shareholders Equity | 5.61B | 592.72M |
| Retained Earnings | 2.15B | -1.08B |
| Retained Earnings % of Revenue | 33.3% | -18.3% |
| Property, Plant & Equipment | 1.07B | 98.89M |
Cash Flow Statement Comparison
| Metric | VENUSREM (2025) | WANBURY (2025) |
|---|---|---|
| Operating Cash Flow | 883.16M | 341.38M |
| Operating Cash Flow % of Revenue | 13.6% | 5.8% |
| Capital Expenditures | -94.27M | 3.97M |
| Free Cash Flow | 683.65M | -229.26M |
| FCF Margin | 10.6% | -3.9% |
| Debt Repayment | -9.54M | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | VENUSREM | WANBURY |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 13.37M | 34.94M |
| Float Shares | 6.37M | 8.30M |
| % Held by Insiders | 48.62% | 47.46% |
| % Held by Institutions | 1.15% | 2.07% |
| % Held by Public | 50.23% | 50.47% |
Dividend Analysis & Yield Comparison: Venus Remedies Ltd. vs Wanbury Ltd.
| Metric | VENUSREM | WANBURY |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | ₹0.00 | ₹0.00 |
| Ex-Dividend Date | N/A | N/A |